FeesSafety
Pluang+

BNB Chain's tokenized stock trading hits $25.6B in Q3 2026, 11x growth from Q2, leading all blockchains.

Protocol Fundamentals
23 Oct 2026
Blockonomi
View Source
Bullish
BNB Chain's tokenized stock trading hits $25.6B in Q3 2026, 11x growth from Q2, leading all blockchains.

In Q3 2026, BNB Chain's tokenized stock trading volume surged to $25.6 billion, about 11 times the previous quarter, driven by the full-quarter launch of bStocks. The network led all blockchains in tokenized stock volume, supply, and holders, with supply doubling to $1.13 billion and 1.8 million holders. Network revenue rose 54% to $54.2 million despite a 14% drop in daily active addresses. The network also completed its 37th quarterly burn, removing 1.646 million BNB tokens worth around $1.2 billion, aiming to reduce total supply to 100 million BNB over time.

BNB Chain's network revenue rose 54% to $54.2 million in Q3 2026, highlighting significant growth in tokenized stock trading volume. For readers following cryptocurrency markets, here is Pluang's market snapshot as of Oct 23, 2026 15:51 WIB: out of 50 major cryptocurrencies, 37 rose and 12 fell today. Notable movers include SXP down 46.27% to Rp37, BAL up 11.14% to Rp16.297, and EOS up 8.13% to Rp12.649.

More News

Zinc and tin supply shortages revive interest in historic US mining districts with new drilling results.

Zinc and tin supply shortages revive interest in historic US mining districts with new drilling results.

Global zinc supply is expected to fall short by 88,000 tonnes in 2026 amid declining mine production, while tin demand is projected to outpace supply growth through 2035. This has renewed exploration in historic polymetallic mining districts in the U...

Market News
Bullish
16 minutes ago
Avacta's AVA6103 shows promise against Enhertu-resistant tumors in early trial and preclinical data

Avacta's AVA6103 shows promise against Enhertu-resistant tumors in early trial and preclinical data

Avacta Therapeutics presented positive preclinical and early clinical data for AVA6103, a novel peptide-drug conjugate targeting FAP-positive tumors resistant to Enhertu. AVA6103 demonstrated superior tumor control and prolonged drug release in precl...

Market News
Bullish
1 hour ago
Obra Capital closes $403.6M CLO deal, pushing total CLO issuance over $2B in under two years.

Obra Capital closes $403.6M CLO deal, pushing total CLO issuance over $2B in under two years.

Obra Capital has closed its fifth Collateralized Loan Obligation (CLO) offering, raising $403.6 million. This deal brings the firm's total CLO issuance to more than $2 billion across five deals in less than two years, demonstrating strong investor co...

Company Fundamentals
Bullish
1 hour ago
Padeliporfin VTP shows promise in making unresectable pancreatic cancer operable in Phase 1 trial

Padeliporfin VTP shows promise in making unresectable pancreatic cancer operable in Phase 1 trial

ImPact Biotech reported positive early results from its Phase 1 trial of Padeliporfin VTP in patients with locally advanced, unresectable pancreatic cancer. Of 12 patients treated, 75% have undergone or are scheduled for surgery, with over half achie...

Company Fundamentals
Bullish
1 hour ago
eSoftware offers a quick diagnostic to help organizations secure sensitive files before Microsoft 365 Copilot rollout.

eSoftware offers a quick diagnostic to help organizations secure sensitive files before Microsoft 365 Copilot rollout.

eSoftware Associates has introduced a free five-minute AI readiness assessment to help regulated organizations identify and prioritize security risks related to sensitive file access in Microsoft 365 before deploying Copilot. The assessment highlight...

Others
Neutral
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App